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BACKGROUND: Colorectal Cancer (CRC) is a major health 
problem around the globe. In Morocco, the disease ranks third after 
breast and lung cancers. This study is the first in Morocco to 
investigate epidemiological, clinical and therapeutic features while 
exhaustively describing toxic side-effects to chemotherapy of CRC 
and studying the 3-years survivorship.  
METHODS: This is a descriptive and analytical retrospective study 
of about 290 patients with CRC enrolled during the period of 
January-December 2013. Statistical analysis was performed to 
correlate clinicopathological data with chemotherapy toxicity and 
survivorship in patients, by Chi2 test. Overall Survival (OS) rate has 
been calculated by the Kaplan-Meier method and compared using 
Log-rank test.  
RESULTS: Fifty-five percent had a tumor localized in rectum, and 
42,8% in colon. Mean age of these patients at diagnosis was 56,16  ± 
14,6. incidence rate of adverse events (grade I to IV) was 85,6%. 
Diarrhea was the predominant toxicity (4.6%) occurring at a high 
grade (grade III-IV). 
The 3-years OS rate of patients with CRC was 71%. OS decreased by 
age, and patients with age subgroup between 40 to 59 years had a 
better OS than the other age subgroups (60 to 79 years and >80 
years) with a p-value of 0.0001. Occurence of toxicity (all grades and 
types) was linked to a higher survival rates compared to the group 
who had no toxicity noticed (p-value of 0.001). 
CONCLUSION: Our study shows that patients who had a 
polychemotherapy had a better OS than those who had monotherapy 
(p-value of 0.002).  
KEYWORDS: Colorectal cancer, chemotherapy toxicities, overall 




Due to its frequency and gravity, colorectal cancer is a major health 
problem around the globe. It is the third most common cancer 
worldwide after lung and breast cancers, in terms of incidence. It ranks 
second in terms of mortality with an estimated 1.8 million new cases 
diagnosed and 881,000 deaths in 2018 according to Global Cancer 
Statistics 2018 (1). 
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A worldwide distribution shows that incidence rates, 
influenced by the lifestyle of populations, are 
elevated in parts of Europe (eg, in Hungary, 
Slovenia, Slovakia, the Netherlands and Norway), 
Australia/New Zealand, Northern America and 
Eastern Asia (Japan and the Republic of Korea, 
Singapore [in females]). It tends to be low or even 
rare in most regions of Africa and Southern Asia (1). 
In Morocco, according to the cancer registry of the 
Greater Casablanca, colorectal cancer is ranking 
third after breast and lung cancers (2). It represents 
6.7% of cancer cases registered between 2008 and 
2012 with a total of 1628 cases.  The standardized 
rates on the world population and the Moroccan 
population were respectively 9.6 and 7.8 new cases 
per 100 000 individual (2) notifying an increasing 
incidence these last years. According to the Rabat 
population-based cancer registry, 4,096 new cases 
are expected to be diagnosed in 2020 (3).  
      In Rabat, the incidence of colorectal cancer 
remains close to the rates in the countries of North 
Africa and East Asia but is still significantly lower 
than rates recorded in developed countries 
(Americas,  Europe, etc.) (3). 
Colorectal cancer, historically known with a 
poor prognosis, has over the years been the subject 
of much research that has changed its treatment. 
Chemotherapy remains a cornerstone of treatment 
for this cancer and for many tumor entities, leading 
to an increased response rate and patient survival. 
This benefit is offset by several toxicities with 
potentially unacceptable life-threatening events and, 
to identical chemotherapy regimen, patients tolerate 
and respond differently. Several factors are 
involved, leading to this inter-individual variability 
such as genetic variability of metabolic enzymes.  
       Nowadays, the identification of patients at high 
risk to encounter toxic adverse events, or at risk of 
treatment failure or either with high chance to 
respond to chemotherapy, is still controversial and 
unclear. Nevertheless, the screening of predictive 
biomarkers could make a considerable progress in 
differentiating prospectively between patients in 
terms of response and tolerance against treatment 
(4). 
The lack of awareness about epidemiology of 
cancers is a major handicap of their treatment. 
Therefore, it is vital to increase our understanding of 
the genetic, environmental and social factors that 
foster these diseases and influence the responses to 
their treatments, with the aim of applying this 
knowledge to effective preventive measures and to 
what cancer epidemiology is dedicated. 
In Morocco, more work is dedicated to 
colorectal cancer to improve medical practice 
diagnostically as therapeutically. It is in this context 
that our work fits, and the main purpose is to study 
the epidemiological, clinical and therapeutic 
characteristics of colon and rectum cancer, 
especially the factors associated with 
chemotherapy-related toxicities and survivorship in 
Moroccan patients with colorectal cancer.  
 
PATIENTS AND METHODS 
 
Study design: This is a descriptive and analytical 
retrospective study of about 290 patients with 
colorectal cancer, confirmed by a histological 
examination. Data were collected from the 
pathological and clinical records of each patient 
during the period of January-December 2013. To 
our best knowledge, this study is the first 
investigation of a Moroccan colorectal cancer 
population, of epidemiological, clinical, and 
therapeutic features notifying and exhaustively 
describing toxic side effects related to chemotherapy 
of colorectal cancer and studying 3 years 
survivorship. 
Data collection and study variables: A 
questionnaire was designed to collect information 
from patients’ medical and clinical records available 
in the registry of the National Institute of Oncology, 
so a complete and comprehensive database was 
made. All demographic, clinical, para-clinical, 
therapeutic characteristics and treatment outcomes 
data were extracted for colorectal cancer patients.  
Treatment and follow-up: The patients received 
treatment according to the Mayoclinic protocols. 
Treatment for colorectal cancer is based on the 
surgery, radiotherapy and chemotherapy; it depends 
on the discovering stage of the cancer. Thus, it’s best 
treated with surgery when it’s discovered at early 
stage. Before each chemotherapeutic cycle or 
chemoradiation, each patient was physically 
examined and any adverse toxic events were 
evaluated and graded for severity according to 
National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (NCI-CTCAE) scales.  
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Patients were followed up until January 2017. 
Overall Survival (OS) was calculated from the date 
of histological diagnosis to the date of death or the 
last follow-up. All patients who are not reviewed in 
the last consultation were contacted again by 
telephone for survivorship assessment. Overall 
Survival (OS) was defined by the period from the 
date of histological diagnosis to the date of the last 
visit or the date of death, regardless of the cause.  
Statistical analysis: Statistical analysis was done by 
SPSS 22.0 software (IBM Corporation, Armonk, 
NY, USA). Descriptive clinical data were expressed 
in percentage or median or mean ± SD. Statistical 
analysis was performed to correlate 
clinicopathological data with chemotherapy toxicity 
and survivorship in patients, by the Chi2 test.  
Statistical significance was set at the p value < 0.05. 
Overall survival rate was calculated by the Kaplan-
Meier method and compared using the Log-rank 
test. Patients lost to follow-up were considered as a 
censored event.  
Ethics approval and consent to participate: The 
local Ethical Committee of Biological Research 
approved the study under the reference number 
409/14. No consent was needed because of the 
retrospective nature of the study. The present 
publication does not compromise anonymity or 
confidentiality or breach local data protection laws.  
RESULTS 
Demographic, clinical and therapeutic 
characteristics of patients: In our series, 290 
patients with colorectal cancer were included. The 
baseline patients’ demographic, clinical and para-
clinical characteristics are listed in Table 1. 
The mean age at diagnosis for patients was 
56,16  ± 14,61 ranging from 24 to 91. There was a 
slight male predominance with 50.5% of men and 
49.5% of women. In our series, 57% of those 
cancers interested the rectum and the colon in 42.8% 
of cases (Table 1). 
According to Table 1, 189 of the patients 
underwent surgery, so the operability rate was 
65.2%; 70 patients had the neoadjuvant concomitant 
chemoradiotherapy (24.1%) and 146 (50.4%) were 
on chemotherapy. The majority of the  
 
Table 1: Demographic, Clinical and paraclinical, 
therapeutic characteristics and outcomes of 
Moroccan patients with colorectal cancer-about 290 
cases. 
 
Characteristics  N (%)                    
Age (mean ± SD) (years) 56.16±14.61 
Sex  
                Male   147 (50.5) 
                Female 144 (49.5) 
Localization   
                   Colon 124(42.8) 
                   Rectum 166(57.2) 
Treatment   
Surgical treatment 189(65.2) 




                 Neoadjuvante 70(24.1) 
                 Exclusive 7(2.4) 
Chemotherapy    
                 Adjuvante 58(20.0) 
                 Neoadjuvant  6(2.1) 
                 Palliative 82(28.3) 
                 Not performed  144(49.7) 
Line 1  
       FOLFIRI/ FOFIRI+bevacizumab 3 (2.1) 
      XELIRI/XELIRI+bevacizumab 1(0.7) 
FOLFOX/FOLFOX+bevacizumab 29(19.8) 
XELOX/XELOX+bevacizumab 107(73.3) 
  XELODA/XELODA+bevacizuma 6(4.1) 
Line 2  
     FOLFIRI/ FOFIRI+bevacizumab 4(2.8) 
     XELIRI/XELIRI+bevacizumab 34(23.3) 
    XELOX/XELOX+bevacizuma    3(2.1) 
Monchemotherapy  4(2.7) 
Polychemotherapy  142(97.3) 
Toxicity (treatment outcomes)  
     Overall toxicity  
            Yes  125(85.6) 
            No   21(14.4) 
Dose reduction/delay/discontinuation/ 
withdrawal  
(due to toxicity) 
 
     Drug dose reduction   9(6.2) 
     Premature discontinuation (ending 
treatment) 
3(2.1) 
     Delay in administration 
(interruption treatment) 
21(14.4) 
     Withdrawal treatment (oxaliplatine 
withdrawn from regimen) 
21(14.4) 
            Yes 125(85.6) 
             No  21(14.4) 
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 patients(n=142, 97%) had polychemotherapy based 
on combination of at least 2 cytotoxic drugs. Mostly, 
in the first line, chemotherapy regimen was based on 
XELOX or XELOX with bevacizumab protocol (in 
73.3% of cases). 
Chemotherapy-related toxicities and 
complications: Table 2 summarizes all toxicity 
events that occurred during chemotherapy for all the 
patients. The incidence rate of adverse events (grade 
I to IV) was 85.6%. Acceptable toxicities were more 
observed than severe toxicities (77.4% grade I-II, 
and 13% grade III-IV) (Table 3). Diarrhea was the 
predominant toxicity (4.6%) occurring with a high 
grade (grade III-IV). 
         The most common grade I-IV (all grades) 
hematologic toxicities were neutropenia (33%), 
anemia (3.2%) and thrombopenia (1.6%). The most 
common grade I-IV (all grades) non-hematologic 
toxicities were peripheral neuropathy (16%), 
nausea/vomiting (48%), diarrhea (45.6%) and hand-
foot syndrome (32%). 
Due to toxicity occurrence, 21 patients (14.4%) had 
dose delay, 14.4% had withdrawal of drug from the 
protocol (oxaliplatine withdrawn), 6.2% required 
dose reduction during therapy, and 2.1% had 
premature discontinuation of chemotherapy. 
Comparison study of Chemotherapy 
Toxicity and related factors: We studied the 
differences between the occurrence of toxic 
events and different demographic, 
clinicopathologic and therapeutic parameters. 
The statistic test did not reveal a significant 
difference, and the comparison with all 
parameters showed a p>0.05 (Table 3).  
Univariate and multivariable logistic regression 
analyses were used, but revealed no significant 
differences in baseline demographic and clinical 
characteristics between the patients who 
encountered toxicities and the patients with no 
toxicity event notified. 
 
Table 2: Chemotherapy-related toxicities reported in patients during treatment 
 
Toxicity type Grade I-IV Grade I-II Grade III-IV 
Number (%) Number (%) Number ( %) 
All types of toxicity 125 (85.6) 113 (77.4) 19  (13.0) 
Hematologic    
    Neutropenia 45 (36.0) 42 (33.6) 4 (3.2) 
    Thrombopenia 2 (1.6) 2 (1.6) 0  (0.0) 
    Anemia 4 (3.2) 2 (1.6) 2 (1.6) 
Gastrointestinal    
   Diarrhea  57 (45.6) 51 (40.8) 6 (4.8) 
   Nausea/vomiting 60 (48.0) 57 (45.6) 4 (3.2) 
Oropharyngeal    
  Mucositis       30 (24.0) 29 (23.2 1 (0.8) 
  Stomatitis  1 (0.8) 1 (0.8) 0 (0.0) 
  Gingivostomatitis 1 (0.8) 1 (0.8) 0 (0.0) 
Dermatological    
  Dermatitis        1 (0.8) (0.8) 0 (0.0) 
  Alopecia  3 (2.4) 3 (2.4) 0 (0.0) 
  Hand and foot syndrome  40 (32.0) 40 (32.0) 0 (0.0) 
 Neurologic    
peripheral neuropathy 76 (60.8) 72 (57.6) 4  (3.2) 
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Localisation    
0.66 Colon 9 (42.9) 60(48.0) 
Rectum 12(57.1) 65(52.0) 
Surgery    
0.41 
 
No 7 (33.3) 31 (24.8) 
Yes 14 (66.7) 94 (75.2) 
CCR    
                       1 No 16(76.2) 96(76.8) 
Yes 5(23.8) 29(23.2) 
RTH    
0.53 No 16(76.2) 96(76.8) 
neoadjuvant 4(19.0) 27(21.6) 
exclusive 1(4.8) 2(1.6) 





adjuvant 8(38.1) 42(33.6) 
neoadjuvant 0(0) 6(4.8) 
pseudoadjuvant 0(0) 8(6.4) 
palliative 13(61.9) 69(56.2) 
CMT lines    
 
0.12 
1 line 18(81.8) 83(69.7) 
2 lines 3(13.6) 33(27.7) 
3 lines 1(4.5) 3(2.5) 
Type of Chemotherapy    
0.46 Mono 1(4.8) 3(2.4) 
Poly 20(95.2) 122(97.6) 
CCR= Concomitant chemoradiotherapy, RTH= Radiotherapy, CMT= Chemotherapy 
 
Survival and outcome: Figure 1 depict the results 
of Kaplan-Meier analysis. The 3-year overall 
survival rate of patients with colorectal cancer was 
71%. Median follow-up was 14 months (14-34) 
with a range of 0– 108 months.  
In our series, overall 3-year survival 
decreased by age. Patients aged 50 years or older 
exhibited a higher mortality rate than patients aged 
less than 50 years with a p-value of 0.04. The 
patients belonging to the age subgroup of between 
40 to 59 years had a better overall survival than the 
other age subgroups (60 to 79 years and >80 years) 
with a p-value of 0.0001 (Figure 1a). Survival rate 
was lower for patients with distant metastasis at 
diagnosis (p-value of 0.0001), and patients 
diagnosed with at least one metastatic site than 
patients with local tumor (p-value of 0.0001) 
(Figure 1b & 1c).  Patients with stage IV at 
diagnosis have a reduced OS, compared to stage II 
and III. (Fig 1d).  
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The study of the relationship between 
treatment and the overall survival reveals that 
patients who had a polychemotherapy had a better 
OS than those who had monotherapy (p-value of 
0.002). For patients with monotherapy, the 
survival was high up to 22 months, then dropped 
to about 65% (Figure 1e).  Moreover, a pseudo-
adjuvant chemotherapy gave a better OS than the 
other chemotherapeutic types (p-value of 0.002) 
(Figures 1e & 1f).  We also noted a better survival 
rate for patients with 2 lines of chemotherapy than 
one-line chemotherapy or none (p-value of 0.002).   
The occurrence of toxicity (all grades and 
types) was linked to a higher survival compared to 
the group who had no toxicity noticed (p-value of 
0.001) (Figure 1g). For rectum cancer patients, the 
OS was significantly higher when chemoradiation 
therapy was administered (p-value of 0.012) 
(Figures 1g & 1h), and with a neoadjuvant 
radiotherapy, the OS increased significantly than 
an exclusive radiotherapy (p-value of 0.02) 
(Figure 1i).   
A significant difference in OS was noted 
between patients who underwent a surgery 
and non-operated patients with a better overall 
survival for the first group. 
There was no significant difference in Kaplan-
Meier analysis, in overall survival between colon 
localization and rectum (p=0.07) and between 
different tumor localizations in colon (p value of 
0.07).
   
 
Figure 1: Overall survival in colorectal cancer patients  
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Figure 1: Overall survival in colorectal cancer patients (continued) 
Key= a- relationship between age (age ranges) and the overall survival (OS), b- relationship between tumor extension 
(metastatic sites) and the OS, c- relationship between presence of metastasis and the OS, d- relationship between stage 
of the tumor at diagnosis and the OS, e- relationship between treatment by chemotherapy and OS, f- relationship between 
types of chemotherapy and the OS, g- relationship between occurrence of toxicity and the OS, h- relationship between 
treatment by chemoradiation and the OS, i- relationship between treatment by radiotherapy and the OS, j- relationship 




We were interested to investigate clinical, 
pathological and therapeutic characteristics and 
outcomes. Overall survival was also an 
interesting feature to analyze.  
In our population study, only 15.2% were aged 
less than 40 years for both males and females; a 
similar rate  was found by a previous study (5). As 
previously described, before the age of 40 years, 
developing colorectal cancer is rare (6), and the risk 
is sharply increasing with age (7).  
On patients’ sex, the distribution of colorectal 
cancer shows a balanced sex ratio, with a slight male 
predominance (50.5% males vs 49.5% females). 
This is in agreement with previous studies (5,8–10). 
In our series, 57% of those cancers interested 
the rectum and the colon in 42.8% of cases. This 
revealed that predilection of the rectum is in 
agreement with previous Moroccan epidemiological 
studies (5), the Moroccan registries and African 
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cohort studies, but  in discordance with the rate 
reported by other European and American studies 
which noted a predominance of colic tumor 
localization (11,12). 
The diagnosis of CRC was in advanced stage 
for 48.6% of cases, otherwise 51.4% of tumors are 
discovered at a relatively early stage (37% in stage 
II, and 14.5% in stage III). However, the cancer 
registry of Rabat (3) reported that “Colon cancer is 
often diagnosed in advanced stages: a quarter of 
cases in stage III and one third of cases in stage 
IV” and for rectal localization “Rectal: more than a 
quarter of cases are diagnosed at stage IV”, 
contradictory to developed countries where the 
earlier stages, I and II, are the most frequent (13). 
        To our knowledge, this is the first 
retrospective study reporting toxic events related to 
chemotherapy in Morocco. A detailed description of 
grades and toxicity types and this one of the several 
strengths of our study. Reporting toxic events is a 
key component of oncological cohort studies and 
randomized controlled trials (RCTs) to evaluate 
patient safety, to improve clinicians’ understanding 
of toxicity and to assess risk-benefit ratios (14). In 
addition, even for international investigations, 
limited data are available on the burden represented 
by all (including low-grade) adverse events (AEs) 
experienced during systemic treatment with 
chemotherapy (15–17).  
In our population study, only 146 underwent 
treatment by chemotherapy, among these, a total of 
125 (85.6%) patients suffered from at least one 
toxicity (any grade), 113(77.4%) patients 
experienced exclusively low-grade (I-II) toxicities, 
and 19 (13%) patients experienced at least one high-
grade toxicity (III-IV). The most common toxicities 
(all grades) were neuropathy (60.8%), nausea and 
vomiting (48%) and diarrhea (45.6%). These 
frequencies are comparable to those reported 
recently by Schuurhuizen et al., 2018 (18).  
  A previous prospective cohort study of older 
adults with cancer reported that 53% of patients 
suffered from at least one grade III to V toxicity 
(39% grade III, 12% grade IV, and 2% grade V 
(chemotherapy-related death). The most common 
grade III to V hematologic toxicities were 
neutropenia (11%). 31% of patients required a dose 
reduction during therapy, 31% had a dose delay, and 
23% were hospitalized during treatment (19). 
   According to NCI-CTCAE, physicians grade 
toxicities and all adverse events (AEs) from low to 
severe (I to V). Grades III and IV commonly urge 
for clinical action(18). 
Indeed, lower grade toxic effects are considered 
as tolerable and often neglected by the clinical trials 
and RCTs limiting reporting to severe toxicities only 
for the total study population (20). Nevertheless, the 
Quality of Life (QOL) of the patient is impacted by 
these long-lasting toxicities even with low grade. 
Furthermore, a recent cohort study by KalsiT et al., 
2014 (21) reported that the accumulation of solely 
grades I–II AEs, considered as low-grade toxicities, 
have clinically impacted older patients, leading to 
discontinuation of their treatment or at least a 
treatment modification (21). 
 In our series, we reported the impact of toxicity 
occurrence (for high grades) on patients’ treatment; 
2.1% had firmly premature chemotherapy 
discontinuation, 14.4% had withdrawal of drug from 
the protocol, 14.4% had dose delay while 6.2% 
required a drug dose reduction. 
       In our series, the 3-year overall survival rate of 
patients with colorectal cancer was 71%. In a 
previous study by ASEVOAIA, 2010 (22), the 5-
year survival rate was 10%. In France, the 5-year 
overall survival rate is about 55% (23).  
In colorectal cancer, locally advanced or 
metastatic, chemotherapy increases survival and the 
patient’s quality of life. It was reported that the 5-
year survival rate increased by 3%–4% when 5-
fluorouracil (5-FU)-based adjuvant chemotherapy 
was administered to patients with stage II colon 
cancer and by 5%–12% for patients with stage III 
colon cancer when compared with surgery alone 
(24).  
The combination of several molecules in a 
chemotherapeutic protocol represents the mainstay 
of the treatment of metastatic colorectal cancer. It 
may be responsible for an increase in response rate, 
as well as an increase in patient survival. Interaction 
analysis showed that the magnitude of risk reduction 
in death from CRC (P < 0.0001) significantly 
differed between chemotherapy recipients and non-
recipients (25).  
Current combination therapies have been 
favored over monotherapy strategies as a result of 
improved response rates, Overall Survival (OS) and 
Progression-Free Survival (PFS) rates. This is in 
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accordance with our study findings as we found that 
the overall survival reveals that patients who had 
polychemotherapy had better OS than those who 
had monotherapy (p-value of 0.002).  
In addition, we found that for rectum cancer 
patients,  neoadjuvant chemoradiotherapy increased 
significantly the OS than an exclusive 
chemoradiotherapy (p-value of 0.02) which is in 
agreement with a controlled study on the survival of 
patients with rectal cancers (26).  Neoadjuvant 
irradiation reduces the risk of loco-regional 
recurrence and increased patient survival.  
Tong et al. found that patients experiencing 
hematological toxicity were less likely to die of 
CRC (0.79, 0.70–0.88) than those without, and that 
patients who experienced gastric toxicity were less 
likely to die of CRC (0.80, 0.77–0.84) than those 
without (19), similar to the finding of our study 
where we report that the occurrence of toxicity (all 
grades and types) was linked to a higher survival 
compared to the group who had no toxicity noticed 
(p-value of 0.001). 
To date, this is the first investigation assessing 
chemotherapy-related toxicities among patients 
under chemotherapy regimens. Because of the lack 
of data on this topic, our study adds relevant 
information and gives reliable figures about the side 
effects of chemotherapy in CRC patients. It shows 
that 85,6% of the patients suffered from at least one 
toxicity (any grade), and 13% of the patients 
experienced at least one high-grade toxicity (III-IV), 
which could not be neglected and should be 
considered as a good indicator of chemotherapy 
tolerability among this population of Moroccan 
colorectal patients.  
The analysis of the OS is another strength of the 
study giving a clear idea about CRC patients’ life 
expectancy in relation with several conditions such 
as stage of the disease, chemotherapy regimen 
combinations and type of treatment underwent. 
Thus, we found that the 3-year overall survival rate 
of patients with colorectal cancer was 71% and that 
the OS was influenced by chemotherapy 
administered, in other words, patients who had a 
polychemotherapy had a better OS than those who 
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